Skip to main content

Advertisement

SpringerLink
Log in

Antibiotic chemotherapy during pregnancy and lactation period: aspects for consideration

  • Materno-fetal Medicine
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Background

Infections during gestation, delivery and the postnatal period can jeopardise not only the mother, but also the child. Along with chromosomal abnormalities and immunological diseases, infection in early pregnancy represents the most important reason for abortion. During the second and third trimester, infections are the principal cause for preterm labour, premature membrane rupture, premature delivery and the resultant complications in the newborn child. Many pregnant women are very cautious about taking antibiotics due to primarily potentially detrimental effects on the unborn child. However, there are no contraindications for antibiotic treatment during pregnancy in the event of a serious infectious disease of the mother.

Materials and methods

In this review the indications and contraindications of the administration of antibiotics during pregnancy are being reviewed.

Results

Penicillins are a first-line antibiotic treatment during pregnancy, with the exception of cases in which there is a maternal allergy to penicillin. Cephalosporins are another first-line antibiotic used during pregnancy. In principle, more commonly used cephalosporins should be given priority. Owing to associated nephrotoxicity and ototoxicity, aminoglycosides should not be prescribed at any time during pregnancy. Systematic use of aminoglycosides should be considered solely in the event of life-threatening infections with gram-negative pathogens and/or treatment failure of recommended antibiotics during pregnancy. The use of metronidazole is also permitted during pregnancy, provided the indications for its use have been strictly verified. Lincosamides should be used only if penicillins, cephalosporins and erythromycin have failed to eradicate infection. Sulfonamides, trimethoprim and cotrimoxazole are second-line agents for the use during pregnancy. Tetracyclines should not be administered to pregnant women after the fifth week of pregnancy, and are deemed contraindicated. As a precautionary measure, gyrase inhibitors are also contraindicated for pregnant women, children and young adolescents.

Conclusion

On the basis of our current state of knowledge, the vast majority of antibiotics do not cause serious harm to the unborn child if used properly and at the appropriate doses during pregnancy. The treatment with an antibiotic that is contraindicated does not justify termination of pregnancy. However, ultimately no medicine, including antibiotics, can be described as absolutely safe.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mylonas I, Dian D, Friese K (2005) Antibiotikatherapie in der Schwangerschaft. Gynakologe 38:761–770

    Article  CAS  Google Scholar 

  2. Mylonas I, Friese K (2009) Infektionen in der Gynäkologien und Geburtshilfe. Elsevier Verlag/Urban & Fischer, München

  3. Friese K, Schäfer A, Hof H (2002) Infektionen in der Gynäkologie und Geburtshilfe. Springer, Berlin

    Google Scholar 

  4. Friese K, Mörike K, Neumann G, Windorfer A (2009) Arzneimittel in der Schwangerschaft und Stillzeit: Ein Leitfaden für Ärzte und Apotheker Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart

  5. Friese K, Melchert F (2002) Arzneimitteltherapie in der Frauenheilkunde. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart

    Google Scholar 

  6. Briggs GG, Freeman RK, Yaffe SJ (1998) Drugs in pregnancy and lactation. Williams & Wilkins, Baltimore

    Google Scholar 

  7. Saunders EJ, Saunders JA (1990) Drug therapy in pregnancy: the lessons of diethylstilbestrol, thalidomide, and bendectin. Health Care Women Int 11:423–432

    Article  CAS  PubMed  Google Scholar 

  8. (2001) Erythromycin-induced pyloric stenosis in infants. Prescrire Int 10:16

  9. Mahon BE, Rosenman MB, Kleiman MB (2001) Maternal and infant use of erythromycin and other macrolide antibiotics as risk factors for infantile hypertrophic pyloric stenosis. J Pediatr 139:380–384

    Article  CAS  PubMed  Google Scholar 

  10. Norgaard M, Skriver MV, Sorensen HT, Schonheyder HC, Pedersen L (2008) Risk of miscarriage for pregnant users of pivmecillinam: a population-based case–control study. APMIS 116:278–283

    PubMed  Google Scholar 

  11. Sa del Fiol F, Gerenutti M, Groppo FC (2005) Antibiotics and pregnancy. Pharmazie 60:483–493

    CAS  PubMed  Google Scholar 

  12. Amann U, Egen-Lappe V, Strunz-Lehner C, Hasford J (2006) Antibiotics in pregnancy: analysis of potential risks and determinants in a large German statutory sickness fund population. Pharmacoepidemiol Drug Saf 15:327–337

    Article  PubMed  Google Scholar 

  13. Bertsche T, Haas M, Oberwittler H, Haefeli WE, Walter-Sack I (2006) Drugs during pregnancy and breastfeeding: new risk categories—antibiotics as a model. Dtsch Med Wochenschr 131:1016–1022

    Article  CAS  PubMed  Google Scholar 

  14. Nahum GG, Uhl K, Kennedy DL (2006) Antibiotic use in pregnancy and lactation: what is and is not known about teratogenic and toxic risks. Obstet Gynecol 107:1120–1138

    Article  CAS  PubMed  Google Scholar 

  15. Haas A, Maschmeyer G (2008) Antibiotic therapy in pregnancy. Dtsch Med Wochenschr 133:511–515

    Article  CAS  PubMed  Google Scholar 

  16. Schäfer C, Spielman H (2001) Arzneimittelverordnung in Schwangerschaft und Stillzeit. Elsevier Urban und Fischer, Berlin, Jena

    Google Scholar 

  17. Dencker BB, Larsen H, Jensen ES, Schonheyder HC, Nielsen GL, Sorensen HT (2002) Birth outcome of 1886 pregnancies after exposure to phenoxymethylpenicillin in utero. Clin Microbiol Infect 8:196–201

    Article  CAS  PubMed  Google Scholar 

  18. Lewis DF, Adair CD, Robichaux AG, Jaekle RK, Moore JA, Evans AT, Fontenot MT (2003) Antibiotic therapy in preterm premature rupture of membranes: are seven days necessary? A preliminary, randomized clinical trial. Am J Obstet Gynecol 188:1413–1416 (discussion 1416–1417)

    Article  CAS  PubMed  Google Scholar 

  19. Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J (2001) Augmentin treatment during pregnancy and the prevalence of congenital abnormalities: a population-based case–control teratologic study. Eur J Obstet Gynecol Reprod Biol 97:188–192

    Article  CAS  PubMed  Google Scholar 

  20. Sigg TR, Kuhn BR (2000) Inadvertent intrauterine infusion of ampicillin–sulbactam. Am J Health Syst Pharm 57:215

    CAS  PubMed  Google Scholar 

  21. Simon C, Stille W (2000) Antibiotika—Therapie in Klinik und Praxis. Schattauer, Stuttgart

    Google Scholar 

  22. Garratty G, Leger RM, Arndt PA (1999) Severe immune hemolytic anemia associated with prophylactic use of cefotetan in obstetric and gynecologic procedures. Am J Obstet Gynecol 181:103–104

    Article  CAS  PubMed  Google Scholar 

  23. Berkovitch M, Segal-Socher I, Greenberg R, Bulkowshtein M, Arnon J, Merlob P, Or-Noy A (2000) First trimester exposure to cefuroxime: a prospective cohort study. Br J Clin Pharmacol 50:161–165

    Article  CAS  PubMed  Google Scholar 

  24. Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J (2001) Use of cephalosporins during pregnancy and in the presence of congenital abnormalities: a population-based, case–control study. Am J Obstet Gynecol 184:1289–1296

    Article  CAS  PubMed  Google Scholar 

  25. Manka W, Solowiow R, Okrzeja D (2000) Assessment of infant development during an 18-month follow-up after treatment of infections in pregnant women with cefuroxime axetil. Drug Saf 22:83–88

    Article  CAS  PubMed  Google Scholar 

  26. Heikkila A, Erkkola R (1994) Review of β-lactam antibiotics in pregnancy. The need for adjustment of dosage schedules. Clin Pharmacokinet 27:49–62

    Article  CAS  PubMed  Google Scholar 

  27. Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J (1999) A population-based case-control teratologic study of oral erythromycin treatment during pregnancy. Reprod Toxicol 13:531–536

    Article  CAS  PubMed  Google Scholar 

  28. Einarson A, Phillips E, Mawji F, D’Alimonte D, Schick B, Addis A, Mastroiacova P, Mazzone T, Matsui D, Koren G (1998) A prospective controlled multicentre study of clarithromycin in pregnancy. Am J Perinatol 15:523–525

    Article  CAS  PubMed  Google Scholar 

  29. Schick B, Hom M, Librizzi R, Donnenfeld A (1996) Pregnancy outcome following exposure to clarithromycin. Reprod Toxicol 10:162

    Google Scholar 

  30. Czeizel AE, Rockenbauer M, Olsen J, Sorensen HT (2000) A case–control teratological study of spiramycin, roxithromycin, oleandomycin and josamycin. Acta Obstet Gynecol Scand 79:234–237

    Article  CAS  PubMed  Google Scholar 

  31. Kallen BA, Otterblad Olausson P, Danielsson BR (2005) Is erythromycin therapy teratogenic in humans? Reprod Toxicol 20:209–214

    PubMed  Google Scholar 

  32. Schardein JL (2000) Chemically induced birth defects. Marcel Dekker, New York

    Google Scholar 

  33. Lewis JH (1991) Drug hepatotoxicity in pregnancy. Eur J Gastroenterol Hepatol 3:883–891

    Google Scholar 

  34. Trexler MF, Fraser TG, Jones MP (1997) Fulminant pseudomembranous colitis caused clindamycin phosphate vaginal cream. Am J Gastroenterol 92:2113

    Google Scholar 

  35. Joesoef M, Schmid G (2002) Bacterial vaginosis. Clin Evid 1592–1600

  36. Czeizel AE, Rockenbauer M, Olsen J, Sorensen HT (2000) A teratological study of aminoglycoside antibiotic treatment during pregnancy. Scand J Infect Dis 32:309–313

    Article  CAS  PubMed  Google Scholar 

  37. Freeman CD, Klutman NE, Lamp KC (1997) Metronidazole: a therapeutic review and update. Drugs 54:679–708

    Article  CAS  PubMed  Google Scholar 

  38. Diav-Citrin O, Gotteiner T, Shechtman S, Arnon J, Ornoy A (2000) Pregnancy outcome following gestational exposure to metronidazole: a prospective controlled cohort study (abstract). Teratology 61:440

    Google Scholar 

  39. Thapa PB, Whitlock JA, Brockman Worrell KG, Gideon P, Mitchel EF, Roberson P, Pais R, Ray WA (1998) Prenatal exposure to metronidazole and risk of childhood cancer. Cancer 83:1461–1468

    Article  CAS  PubMed  Google Scholar 

  40. Beard CM, Noller KL, O’Fallon WM, Kurland LT, Dahlin DC (1988) Cancer after exposure to metronidazole. Mayo Clin Proc 63:147–153

    CAS  PubMed  Google Scholar 

  41. Caro-Paton T, Carvajal A, Martin de Diego I, Martin-Arias LH, Alvares-Requejo A, Rodriguez-Pinilla E (1997) Is metronidazole teratogenic? A meta-analysis. Br J Clin Pharmacol 44:179–182

    Article  CAS  PubMed  Google Scholar 

  42. Czeizel AE, Rockenbauer M (1998) A population based case-control teratologic study of oral metronidazole treatment during pregnancy. Br J Obstet Gynaecol 105:2–7

    Google Scholar 

  43. Czeizel AE (1990) A case–control analysis of the teratogenic effects of co-trimoxazole. Reprod Toxicol 4:305–313

    Article  CAS  PubMed  Google Scholar 

  44. Heinonen OP, Slone D, Shapiro S (1977) Birth defects and drugs in pregnancy. Publishing Sciences Group, Littleton

    Google Scholar 

  45. Friese K, Hlobil H (1997) Prenatal toxoplasmosis: is screening in pregnancy necessary? Z Geburtshilfe Neonatol 201:115–120

    CAS  PubMed  Google Scholar 

  46. Friese K (1994) Diagnosis and treatment of congenital toxoplasmosis. Geburtshilfe Und Frauenheilkunde 54:M99–M101

    CAS  PubMed  Google Scholar 

  47. Wenk RE, Gebhardt FC, Bhagavan BS, Lustgarten JA, McCarthy EF (1981) Tetracycline-associated fatty liver of pregnancy, including possible pregnancy risk after chronic dermatologic use of tetracycline. J Reprod Med 26:135–141

    CAS  PubMed  Google Scholar 

  48. Whalley PJ, Martin FG, Adams RH, Combes B (1970) Disposition of tetracycline by pregnant women with acute pyelonephritis. Obstet Gynecol 36:821–826

    CAS  PubMed  Google Scholar 

  49. Czeizel AE, Rockenbauer M (2000) A population-based case–control study of oral oxytetracycline treatment during pregnancy. Eur J Obstet Gynecol Reprod Biol 88:27–33

    Article  CAS  PubMed  Google Scholar 

  50. Takayama S, Watanabe T, Akiyama Y, Ohura K, Harada S, Matsuhashi K, Mochida K, Yamashita N (1986) Reproductive toxicity of ofloxacin. Arzneimittelforschung 36:1244–1248

    CAS  PubMed  Google Scholar 

  51. Gough AW, Kasali OB, Sigler RE, Baragi V (1992) Quinolone arthropathy acute toxicity to immature articular cartilage. Toxicol Pathol 20:436–449

    Article  CAS  PubMed  Google Scholar 

  52. Schaefer C, Amoura-Elefant E, Vial T, Ornoy A, Garbis H, Robert E, Rodriguez-Pinilla E, Pexieder T, Prapas N, Merlob P (1996) Pregnancy outcome after prenatal quinolone exposure. Evaluation of a case registry of the European Network of Teratology Information Services (ENTIS). Eur J Obstet Gynecol Reprod Biol 69:83–89

    Article  CAS  PubMed  Google Scholar 

  53. Berkovitch M, Pastuszak A, Gazarian M, Lewis M, Koren G (1994) Safety of the new quinolones in pregnancy. Obstet Gynecol 84:535–538

    CAS  PubMed  Google Scholar 

  54. Loebstein R, Addis A, Ho E, Andreou R et al (1998) Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study. Antimicrob Agents Chemother 42:1336–1339

    CAS  PubMed  Google Scholar 

  55. Holdiness MR (1987) Teratology of the antituberculosis drugs. Early Hum Dev 15:61–74

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The author would like to thank Prof. Dr. E.-R. Weissenbacher and Prof. Dr. K. Friese for their helpful discussion regarding antibiotic treatment during pregnancy and lactation period. The author does not have any financial, personal, political, intellectual or religious interests in publishing this article.

Author information

Authors and Affiliations

  1. Division of Infectious Diseases in Gynaecology and Obstetrics, 1st Department of Obstetrics and Gynaecology, Ludwig-Maximilians-University Munich, Maistrasse 11, 80337, Munich, Germany

    Ioannis Mylonas

Authors
  1. Ioannis Mylonas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ioannis Mylonas.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mylonas, I. Antibiotic chemotherapy during pregnancy and lactation period: aspects for consideration. Arch Gynecol Obstet 283, 7–18 (2011). https://doi.org/10.1007/s00404-010-1646-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-010-1646-3

Keywords

Search

Navigation